# Efficacy of 5-ALA Photodynamic Therapy in Dysplastic Oral Leukoplakia: Systematic Review and Meta-Analysis

**Authors:** Magdalena Sulewska, Patryk Wiśniewski, Monika Stępniewska, Zuzanna Poloczek, Dawid Chodziński, Piotr Melion, Maksymilian Pawluczuk, Aleksandra Pietruska, Małgorzata Pietruska

PMC · DOI: 10.3390/pharmaceutics18020254 · Pharmaceutics · 2026-02-18

## TL;DR

This study reviews the effectiveness of 5-ALA photodynamic therapy for treating dysplastic oral leukoplakia, finding it promising but highlighting the need for more research.

## Contribution

The paper provides the first systematic quantification of 5-ALA photodynamic therapy's efficacy in treating dysplastic oral leukoplakia.

## Key findings

- Pooled overall response rate was 85% with moderate to substantial heterogeneity.
- Complete response rate was 34%, but recurrence and malignant transformation risks remain.
- Evidence certainty is rated as very low, underscoring the need for controlled studies.

## Abstract

Background: Oral leukoplakia (OL) with oral epithelial dysplasia (OED) carries an increased risk of malignant transformation and typically requires active management and long-term surveillance. Surgical excision remains the gold standard, yet recurrence is common and morbidity may be substantial, particularly in extensive or multifocal disease. Photodynamic therapy using 5-aminolevulinic acid (ALA-PDT) has emerged as a minimally invasive alternative. However, its effectiveness in dysplastic OL has not been quantified systematically. Methods: A systematic review and meta-analysis were conducted according to a prospectively registered protocol (PROSPERO: CRD420251249586) and reported in line with PRISMA 2020. PubMed, Scopus, and Web of Science were searched from inception to 15 December 2025 for clinical studies evaluating ALA-PDT as primary treatment for OL with histopathologically confirmed OED. Single-arm prospective or retrospective studies reporting clinical response were eligible. Risk of bias was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Case Series. Pooled overall response rate (ORR) and complete response (CR) were estimated as proportions using random-effects models. Recurrence and malignant transformation were summarized as incidence rates per 100 person-years. Results: Six single-arm clinical studies including 109 patients with dysplastic oral leukoplakia treated with 5-ALA-mediated photodynamic therapy were eligible for quantitative synthesis. The pooled overall response rate was 0.85 (95% CI 0.74–0.93), whereas the pooled complete response rate reached 0.34 (95% CI 0.18–0.53), with moderate to substantial heterogeneity. Recurrence and malignant transformation outcomes were limited and analyzed descriptively, suggesting low but persistent long-term risk. The overall certainty of the evidence was rated as very low according to GRADE. Conclusions: 5-ALA-mediated photodynamic therapy appears to be an effective and minimally invasive treatment option for oral leukoplakia with epithelial dysplasia; however, the very low certainty of evidence, lack of standardized protocols, and persistent risk of recurrence and malignant transformation highlight the need for well-designed controlled studies and long-term clinical surveillance.

## Linked entities

- **Chemicals:** 5-aminolevulinic acid (PubChem CID 137)
- **Diseases:** oral leukoplakia (MONDO:0004844)

## Full-text entities

- **Genes:** FECH (ferrochelatase) [NCBI Gene 2235] {aka EPP, EPP1, FCE}
- **Diseases:** injury to (MESH:D014947), hereditary disorders (MESH:D009386), dysplasia (MESH:D015792), carcinoma in situ (MESH:D002278), Malignant transformation (MESH:D009369), oral lichen planus (MESH:D017676), OED (MESH:C567703), HPV infections (MESH:D030361), CR (MESH:D001766), Dysplastic (MESH:D004416), squamous cell carcinoma (MESH:D002294), OSCC (MESH:D000077195), nutritional deficiencies (MESH:D044342), carcinogenic (MESH:D011230), OL (MESH:D007972), oral disorders (MESH:D009056), transformation (MESH:D002472), cytotoxicity (MESH:D064420), erosions (MESH:D014077), oral mucosal disorders (MESH:D013280), OPMD (MESH:C537245), Leukoplakia (MESH:D007971)
- **Chemicals:** PpIX (MESH:C028025), oxygen (MESH:D010100), ALA (MESH:D000409), carotenoids (MESH:D002338), vitamin A (MESH:D014801), 5-ALA (MESH:C000614854), retinoids (MESH:D012176), 5-ALA"[Title (-), heme (MESH:D006418), 5-ALA (MESH:D000622), CO2 (MESH:D002245), alcohol (MESH:D000438), reactive oxygen species (MESH:D017382)
- **Species:** Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12944706/full.md

## Figures

10 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12944706/full.md

## References

91 references — full list in the complete paper: https://tomesphere.com/paper/PMC12944706/full.md

---
Source: https://tomesphere.com/paper/PMC12944706